Yahoo
NYSE American - Delayed Quote USD

Can-Fite BioPharma Ltd. (CANF)

2.9300 -0.2600 (-8.15%)
At close: May 1 at 4:00:00 PM EDT
2.9200 -0.0100 (-0.34%)
After hours: May 1 at 7:57:29 PM EDT
Chart Range Bar
Loading chart for CANF
  • Previous Close 3.1900
  • Open 3.2400
  • Bid 2.9200 x 50000
  • Ask 2.9400 x 190000
  • Day's Range 2.8900 - 3.0900
  • 52 Week Range 2.8300 - 24.0000
  • Volume 540,419
  • Avg. Volume 1,135,954
  • Market Cap (intraday) 6.278M
  • Beta (5Y Monthly) -0.10
  • PE Ratio (TTM) --
  • EPS (TTM) -10.7500
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 50.00

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

www.canfite.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: CANF

View More

Performance Overview: CANF

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

CANF
18.61%
TA-125 (^TA125.TA)
19.60%

1-Year Return

CANF
86.56%
TA-125 (^TA125.TA)
70.94%

3-Year Return

CANF
91.58%
TA-125 (^TA125.TA)
148.19%

5-Year Return

CANF
99.32%
TA-125 (^TA125.TA)
0.00%

Earnings Trends: CANF

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY25
Revenue 101k
Earnings --

Q2

FY23

Q3

FY23

Q4

FY23

Q2

FY25

-2M
-1M
-500K
0

Analyst Insights: CANF

View More

Analyst Price Targets

50.00
50.00 Average
2.9300 Current
50.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 12/24/2025
Analyst D. Boral Capital
Rating Action Downgrade
Rating Hold
Price Action --
Price Target --

Statistics: CANF

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    6.66M

  • Enterprise Value

    -1.81M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.62

  • Price/Book (mrq)

    1.12

  • Enterprise Value/Revenue

    0.92

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -66.75%

  • Return on Equity (ttm)

    -178.24%

  • Revenue (ttm)

    405k

  • Net Income Avi to Common (ttm)

    -9.83M

  • Diluted EPS (ttm)

    -10.7500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.54M

  • Total Debt/Equity (mrq)

    1.27%

  • Levered Free Cash Flow (ttm)

    -4.99M

Compare To: CANF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CANF

Fair Value

2.9300 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: